Your sleep history during middle age may predict Alzheimer's pathology later in life. A decrease in sleep quality between 50 and 70 years of age is associated with higher levels of tau and amyloid beta in the brain. Changes in brain activity and quality of sleep could be a biomarker for Alzheimer's disease.
According to a new study, slow walking speed may signify a build up of amyloid plaques in elderly people, even if they do not have other symptoms of Alzheimer's disease.
According to researchers, odor identification tests could prove useful in predicting cognitive decline and detecting early stage Alzheimer's disease.
Smokers may have reduced neuroimmune function compared to their non-smoking peers. Researchers report restoring the immune system may benefit smokers. Immune dysfunction is linked to cognitive dysfunction.
Cigarette smoking activates dopamine driven satisfaction and pleasure responses differently between the sexes, a neuroimaging study finds.
Researchers find the opioid system responds to social rejection, not just physical pain.
A new study reveals people with schizophrenia have a disrupted stress response. Researchers report those with schizophrenia have an increase in dopamine release in the striatum, but not in the prefrontal cortex, in response to stress.
Neuroimaging study reveals decreased levels of the SV2A protein in synapses in patients with schizophrenia. The decrease in the protein could underlie the cognitive difficulties experienced by those with schizophrenia and provide new targets for treatment.
PET neuroimaging reveals super-agers and those whose cognitive skills are above the norm for an advanced age have an increased resistance to tau and amyloid proteins.
Researchers report measures of tau are better markers of cognitive decline in Alzheimer's disease than measures of amyloid beta seen on PET scans.